Sepranolone: A New Treatment for PMDD?
In this phase II study, sepranolone 10 mg administered subcutaneously during the late luteal phase reduced PMDD symptoms more than placebo.
In this phase II study, sepranolone 10 mg administered subcutaneously during the late luteal phase reduced PMDD symptoms more than placebo.
Some, but not all, studies suggest that PMDD is a risk factor for postpartum depression.
In a recent meta-analysis, Yan and colleagues looked at the prevalence of suicidal ideation among women diagnosed with PMDD.
In an evidence-based review published in 2012, Laura Wakil, Samantha Meltzer-Brody, and Susan Girdler present a thorough review of premenstrual dysphoric disorder (PMDD), reviewing its diagnosis and treatment options.
There is excellent data to support the use of selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs and SNRIs) for the treatment of premenstrual dysphoric disorder (PMDD); however, many women do not want to take [...]
Not infrequently we see women who ask about the possibility of oophorectomy (surgical removal of the ovaries) as a means of managing what appears to be a menstrually related mood disorder. While this is an [...]
Brexanolone, to be marketed by Sage Therapeutics as Zulresso, was initially approved in March 2019, as a treatment for postpartum depression. At that time, we were told that Zulresso would be available in June 2019. [...]
Chasteberry, the fruit of the chaste tree or Vitex agnus castus, has long been touted as a remedy for a range of reproductive problems, including premenstrual symptoms or PMS. Two recent publications have reviewed data [...]